Beiersdorf Aktiengesellschaft Stock Timeline

May 2021

Vincent Warnery appointed Chief Executive Officer effective 1 May 2021, following Stefan De Loecker's departure and an Executive Board reshuffle. The market interpreted the leadership transition as continuity paired with sharper strategic focus around C.A.R.E.+ (sustainability, innovation, digitalisation, growth). The business was exiting the worst pandemic effects, and the stock entered a recovery-phase uptrend. [12], [14], [24], [21], [1]

FY 2021 (reported Mar 1, 2022)

Group sales reached €7,627m with organic growth of 9.7%; Consumer sales €6,129m (organic +8.8%). The company reported progress on C.A.R.E.+ initiatives and EBIT excluding special factors around 13.0%. Investor perception shifted from pandemic recovery to operational stability — Beiersdorf began to be viewed as a low-single to mid-single-digit organic growth compounder. The stock rallied on confirmatory fundamentals. [1], [3], [11], [21]

2022 — broad-based acceleration

Strong, broad-based growth throughout 2022 pushed group sales toward €8.8bn. Management repeatedly reported double-digit organic growth trends and raised visibility. The market increasingly regarded Beiersdorf as a growth story again, with outperformance in Consumer and strong tesa contribution. The stock broke out and sustained an uptrend as investors rewarded accelerating top-line and margin stability. [13], [18], [25], [32]

FY 2023 (reported Feb 29, 2024)

Record Group sales of €9.5bn (organic +10.8%); Consumer €7.8bn (organic +12.5%); NIVEA exceeded €5bn (NIVEA +16.2%); Derma grew 24%. The board proposed a dividend increase to €1.00 and approved a share buyback program up to €500m. The market framed Beiersdorf as the fastest-growing beauty company in its peer group, with narrative shifting to growth plus direct shareholder returns. The stock rallied on strong results and capital-return plans. [31], [35], [36]

FY 2024 (reported Feb 25, 2025)

Record FY2024 sales of €9,850m (organic +6.5%); EBIT excluding special factors €1,370m (EBIT margin 13.9%); the company continued significant investments. Year-end share price closed at €124.00. Execution and margin progress reinforced the quality-compounder story, but investors began taking profits after a multi-year run. The stock entered a plateau and consolidation phase. [28], [32], [36]

Q1–H1 2025 (Apr–Aug 2025)

Q1 2025: Group organic growth +3.6% (nominal +3.3%); Derma and tesa strongly outperformed, while La Prairie posted a steep Q1 decline of -17.5%. The Board approved another buyback program (up to €500m) in February 2025. H1 2025: Group sales €5.2bn (organic +2.1%); EBIT excluding special factors €836m (EBIT margin 16.1%). The company trimmed FY 2025 Consumer sales guidance to 3–4% (from 4–6%) and reduced expected margin uplift. Market tone shifted to caution as slowing end-markets, China repositioning and travel-retail destocking raised doubts about near-term growth despite Derma strength and buybacks. The stock entered a corrective phase with rising volatility. [37], [38], [39], [41]

FY 2025 (reported Mar 2, 2026)

Full-year 2025: Group sales €9.9bn, organic growth +2.4%. Derma again outperformed, but overall group growth materially decelerated versus 2023–24. Investors re-priced the stock toward a more mature, cyclical profile with emphasis on margin management, buybacks and Derma resilience while luxury and travel retail remained headwinds. The stock extended its downtrend into 2026 with materially lower multiples and significant share-price retracement. [44], [41]